Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV |
| 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 36 | University of California, DavisOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | recruiting | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06565689 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | recruiting | Phase 1 | 48 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis(ALANIS) | recruiting | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04712539 | Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04968834 | Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens | recruiting | — | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | recruiting | Phase 1 | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | recruiting | Phase 2 | 52 | Irene Ghobrial, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05929612 | A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06102330 | Multicenter HomeVENT: Home Values and Experiences Navigation Track(HomeVENT) | recruiting | N/A | 600 | Johns Hopkins UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06207812 | Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06469307 | Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)(DIVERSE) | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06498973 | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 43 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | recruiting | Phase 2 | 128 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | recruiting | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.(Withaferin_A) | recruiting | Phase 2 | 34 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709013 | Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients | recruiting | Phase 2 | 22 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04981821 | A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms(GO-EXCAP2) | recruiting | N/A | 170 | University of RochesterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05464719 | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06928909 | Leukemia Adapted Protocol(LEAP) | recruiting | — | 30 | Baylor College of MedicineOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705178 | More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)(MaximALL) | recruiting | N/A | 180 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04656431 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma | recruiting | Phase 1 | 26 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04659616 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 32 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | recruiting | Phase 1 / Phase 2 | 35 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | recruiting | — | 247 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | recruiting | Phase 2 | 62 | Mayo ClinicOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | recruiting | Phase 4 | 850 | St. Jude Children's Research HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06340646 | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) | recruiting | N/A | 990 | Washington University School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06594445 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | recruiting | Phase 1 | 45 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07082868 | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | recruiting | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03308474 | Myeloma Registry Platform (MYRIAM)(MYRIAM) | recruiting | — | 2,200 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03555851 | Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy | recruiting | — | 120 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 20, 2026source: clinicaltrials